Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 2 1

Status

Completed 6Unknown 5Terminated 3Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 2Tumor-Agnostic 1NET 1Gastrointestinal 1

Conditions

Pituitary Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Gigantism 1Gastrointestinal Neoplasms 1Carcinoid Tumor 1Acromegaly 1

Interventions

Cyclophosphamide 240Radiotherapy 216Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Rituximab 141Capecitabine 141pembrolizumab 139Oxaliplatin 124Nivolumab 124Dexamethasone 122Fluorouracil 113fludarabine 103Radiosurgery 101Doxorubicin 99fludarabine phosphate 96Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 91Magnetic Resonance Spectroscopy 90Radiation 89Leucovorin 88Filgrastim 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × OTHER × lanreotide × Clear all
NCT02859064 2023-12-05

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

SCRI Development Innovations, LLC

Phase 2 Terminated
6 enrolled 12 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Gastrointestinal Neoplasms, Neuroendocrine Tumors

NCT02288377 2023-01-18

REMINET

Federation Francophone de Cancerologie Digestive

Phase 2/3 Terminated
53 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01861717 2021-09-30

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

Saint John's Cancer Institute

Phase 4 Terminated
4 enrolled 5 charts
Endocrine

Acromegaly, Gigantism, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡